Synthekine is developing an innovative combination therapy of SYNCAR-001 and STK-009, leveraging IL-2 pathway modulation for treating refractory chronic lymphocytic leukemia.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.